{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:16:16Z","timestamp":1761293776013,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ecl.2018.04.003","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T01:21:42Z","timestamp":1531272102000},"page":"505-523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Novel Functional Imaging of Neuroendocrine Tumors"],"prefix":"10.1016","volume":"47","author":[{"given":"Anders","family":"Sundin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2018.04.003_bib1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"48","author":"Gabriel","year":"2007","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2967\/jnumed.109.066134","article-title":"The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy","volume":"51","author":"Srirajaskanthan","year":"2010","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","article-title":"The impact of 68Ga-DOTATOC positron emission tomography\/computed tomography on the multimodal management of patients with neuroendocrine tumors","volume":"252","author":"Frilling","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.ecl.2018.04.003_bib4","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s00330-015-3882-1","article-title":"Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET\/CT: a lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours","volume":"26","author":"Van Binnebeek","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ecl.2018.04.003_bib5","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2967\/jnumed.113.120600","article-title":"Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors","volume":"54","author":"Sandstr\u00f6m","year":"2013","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0284185113496679","article-title":"Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis","volume":"55","author":"Yang","year":"2014","journal-title":"Acta Radiol"},{"key":"10.1016\/j.ecl.2018.04.003_bib7","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2217\/fon.14.139","article-title":"PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature","volume":"10","author":"Johnbeck","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.ecl.2018.04.003_bib8","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s00259-013-2482-z","article-title":"Somatostatin receptor PET\/CT in neuroendocrine tumours: update on systematic review and meta-analysis","volume":"40","author":"Geijer","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ecl.2018.04.003_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12020-012-9631-1","article-title":"Diagnostic performance of Gallium-68 somatostatin receptor PET and PET\/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis","volume":"42","author":"Treglia","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.ecl.2018.04.003_bib10","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","article-title":"68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors","volume":"52","author":"Poeppel","year":"2011","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2967\/jnumed.113.126177","article-title":"Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification","volume":"55","author":"Velikyan","year":"2014","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00259-013-2342-x","article-title":"18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type","volume":"40","author":"Balogova","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ecl.2018.04.003_bib13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","article-title":"Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours","volume":"35","author":"Ambrosini","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ecl.2018.04.003_bib14","first-page":"68","article-title":"Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients","volume":"54","author":"Putzer","year":"2010","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ecl.2018.04.003_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/cancers4010100","article-title":"PET-guided surgery - high correlation between positron emission tomography with 11C-5-Hydroxytryptophane (5-HTP) and surgical findings in abdominal neuroendocrine tumours","volume":"4","author":"Orlefors","year":"2012","journal-title":"Cancers"},{"key":"10.1016\/j.ecl.2018.04.003_bib16","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1210\/jc.2004-1938","article-title":"Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography","volume":"90","author":"Orlefors","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2018.04.003_bib17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2007.15.1126","article-title":"Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography","volume":"26","author":"Koopmans","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ecl.2018.04.003_bib18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2967\/jnumed.115.167445","article-title":"Glucagon-like peptide-1 receptor PET\/CT with 68Ga-NOTA-Exendin-4 for detecting localized insulinoma: a prospective cohort study","volume":"57","author":"Luo","year":"2016","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.109.069765","article-title":"Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET","volume":"51","author":"Binderup","year":"2010","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib20","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2967\/jnumed.114.142224","article-title":"Can complementary 68Ga-DOTATATE and 18F-FDG PET\/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?","volume":"55","author":"Has Simsek","year":"2014","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"16","author":"Binderup","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ecl.2018.04.003_bib22","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.114.144386","article-title":"High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation","volume":"55","author":"Bahri","year":"2014","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib23","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2967\/jnumed.109.066639","article-title":"A\u00a0comparison of 68Ga-DOTATATE and 18F-FDG PET\/CT in pulmonary neuroendocrine tumors","volume":"50","author":"Kayani","year":"2009","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib24","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1245\/s10434-015-4471-x","article-title":"Octreoscan versus FDG-PET for neuroendocrine tumor staging: a biological approach","volume":"22","author":"Squires","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.003_bib25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00268-017-4364-1","article-title":"Preoperative 68Ga-DOTA-somatostatin analog-PET\/CT hybrid imaging increases detection rate of intra-abdominal small intestinal neuroendocrine tumor lesions","volume":"42","author":"Norl\u00e9n","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.ecl.2018.04.003_bib26","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s00261-015-0409-9","article-title":"Simultaneous (68)Ga-DOTA-TOC PET\/MRI with gadoxetate disodium in patients with neuroendocrine tumor","volume":"40","author":"Hope","year":"2015","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.ecl.2018.04.003_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/RLI.0b013e3182871a7f","article-title":"Simultaneous 68Ga-DOTATOC PET\/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results","volume":"48","author":"Beiderwellen","year":"2013","journal-title":"Invest Radiol"},{"key":"10.1016\/j.ecl.2018.04.003_bib28","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1007\/s00330-013-2785-2","article-title":"Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET\/MRI in patients with neuroendocrine tumours of the upper abdomen","volume":"23","author":"Mayerhoefer","year":"2013","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ecl.2018.04.003_bib29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/RLU.0000000000001753","article-title":"Whole-body 68Ga-DOTANOC PET\/MRI versus 68Ga-DOTANOC PET\/CT in patients with neuroendocrine tumors: a prospective study in 28 patients","volume":"42","author":"Berzaczy","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib30","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1007\/s00330-017-4803-2","article-title":"Evaluation of 68Ga-DOTATOC PET\/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET\/CT","volume":"27","author":"Sawicki","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ecl.2018.04.003_bib31","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00330-011-2266-4","article-title":"Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours","volume":"22","author":"Schreiter","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ecl.2018.04.003_bib32","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","article-title":"Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study","volume":"55","author":"Wild","year":"2014","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib33","article-title":"Safety, biodistribution, and radiation dosimetry of 68Ga-OPS202 (68Ga-NODAGA-JR11) in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase I imaging study","author":"Nicolas","year":"2017","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib34","article-title":"Comparison of 68Ga-OPS202 (68Ga-NODAGA-JR11) and 68Ga-DOTATOC (68Ga-Edotreotide) PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: evaluation of sensitivity in a prospective phase II imaging study","author":"Nicolas","year":"2017","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.003_bib35","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2967\/jnumed.117.191684","article-title":"Biodistribution, pharmacokinetics, and dosimetry of 177Lu-, 90Y-, and 111In-labeled somatostatin receptor antagonist OPS201 in comparison to the agonist 177Lu-DOTATATE: the mass effect","volume":"58","author":"Nicolas","year":"2017","journal-title":"J\u00a0Nucl Med"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852918305152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852918305152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:41:55Z","timestamp":1760175715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852918305152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0889852918305152"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2018.04.003","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Functional Imaging of Neuroendocrine Tumors","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2018.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}